Evening Brief: China's Space Station Experiment Offers New Hope for Fatty Liver Disease Affecting Over 1.7 Billion; Brain-Computer Interface Breakthrough Tackles Post-Stroke Disabilities

1. Over 1.7 Billion People Affected Worldwide: China Space Station Experiments Hold Promise for New Therapies

Over 1.7 billion people worldwide are affected by fatty liver disease, with the prevalence among adults in China reaching approximately 30%. It is therefore urgent to explore the pathogenic mechanisms and treatment strategies. The research titled “Impact of Space-Based Biophase Separation on Lipid Metabolism,” currently being conducted on the Chinese Space Station, holds promise for providing new insights into the prevention and treatment of fatty liver disease. On June 1, the seven-day on-orbit experiment concluded successfully. According to Li Ning, an associate researcher at the Institute of Mechanics, Chinese Academy of Sciences, the space microgravity environment exerts a significant regulatory effect on hepatic cell metabolism, and the experiment aims to identify the underlying regulatory mechanisms under microgravity. The mechanical microenvironment of the liver is complex; during the progression of diseases such as liver fibrosis or fatty liver, changes in this mechanical microenvironment significantly regulate hepatocyte function. Scientists believe that fluid shear stress is the most direct mechanical factor leading to abnormal hepatic lipid metabolism. The microgravity environment reduces the mechanical effects of blood flow on the liver, thereby exacerbating fat accumulation. Experiments conducted during China’s Shenzhou-16 mission have already identified the metabolic “culprit” under microgravity conditions, and the current experiment aims to discover the “upstream switch” that activates SREBP.

2. Can Brain-Computer Interfaces Address Post-Stroke Sequelae? Two Industry Leaders Join Forces to Achieve a Medical Breakthrough with an Interventional Approach

The sequelae of stroke cause immense suffering to patients and their families. China has an existing population of approximately 15 to 18 million stroke survivors, with the incidence rate continuing to rise. The prevalence of post-stroke motor dysfunction is high, while the basic recovery rate of hand function remains low. Furthermore, stroke is showing a trend toward affecting younger individuals. In the face of this vast unmet clinical need, brain-computer interfaces (BCIs) are held in high expectation. OYMotion and Minimally Invasive Brain Science (Suzhou) Co., Ltd. are collaborating to develop an "Interventional Brain-Computer Interface Rehabilitation System," exploring new pathways for stroke rehabilitation. This system adopts a minimally invasive vascular intervention approach, enabling the acquisition of high-quality intracranial electroencephalogram (EEG) signals without craniotomy, thereby balancing safety with signal precision. OYMotion believes its product meets three criteria: clear market demand, genuine clinical benefit, and definite commercial value. The system also integrates lightweight exoskeleton robotics, converting decoded signals into motion control commands to drive the exoskeleton and assist users in performing movements.

3. A Chinese Nucleic Acid Drug Startup Completes Angel+ Round of Financing

Yimu Biologics, an emerging player in the field of nucleic acid therapeutics, has announced the completion of its Angel+ round of financing. The round was led by Bencao Capital, with participation from several strategic institutional investors; information regarding the financial advisor was not disclosed. Founded in 2024, Yimu Biologics was co-established by Professor Zhang Chuan from Shanghai Jiao Tong University and Director Hong Jiaxu from Fudan University. The funds raised in this round will be primarily used to advance clinical trials for core pipeline assets, support R&D for key pipelines and the screening and validation of candidate pipelines, as well as to strengthen organizational and talent development. The company has independently built two major technology platforms to develop novel nucleic acid-modified therapeutics and has established a product pipeline targeting multiple indications. Notably, its core asset, YM-101, has completed investigator-initiated trials (IIT) and is accelerating toward Investigational New Drug (IND) application submission, while subsequent candidates such as YM-102 and YM-103 are progressing steadily.

4. After Carrying a Lethal Gene for 20 Years, This Scientist Decided to Abandon Research and Join a $400 Million High-Stakes Gamble

Jeff Carroll, 48, is an associate professor at the University of Washington whose research focuses on Huntington’s disease. More than two decades ago, he was diagnosed as a carrier of the gene for this rare disorder, which also claimed his mother’s life. Huntington’s disease is an autosomal dominant neurodegenerative disorder that typically manifests in one’s thirties or forties, leads to death within 15 to 20 years after onset, and currently has no cure. After dropping out of high school, Jeff joined the U.S. Army and began studying the disease after learning of his mother’s diagnosis. He later pursued university correspondence courses. In 2003, genetic testing revealed that he carried 42 CAG repeats, indicating that he would inevitably develop the disease. Now, Jeff has decided to leave academic research and join the Allen Institute’s “Accelerating Brain Health” initiative, which aims to expedite the development of targeted therapies for multiple neurodegenerative diseases, with the goal of advancing the first experimental gene therapy into human clinical trials within five years.

5. Organizational Restructuring Establishes the Pan-Asia-Pacific Region, Accelerating the Implementation of InnoCare’s Strategic Transformation

Yiboda Accelerates Strategic Transformation with Key Steps in Organizational Structure and Industrial LayoutYiboda is accelerating the implementation of its strategic transformation, taking critical steps in organizational restructuring and industrial layout. On one hand, it has integrated its former Greater China and Asia operations to establish a new Pan-Asia-Pacific organizational structure, appointing Huang Xuemei as Vice President and General Manager. This move will empower the company by enhancing regional resource integration and operational efficiency, precisely matching diverse market demands, and building a robust talent pipeline. On the other hand, Yiboda has completed the acquisition and integration of Owen Mumford, a long-established UK-based enterprise, thereby expanding its product portfolio and technological capabilities. Yiboda’s strategic transformation is not a short-term decision but stems from an in-depth analysis of industry trends and its own development trajectory. As the global market for chronic disease management expands, companies must pursue diversified development. Organizational innovation has become the core lever for implementing this strategy, with Yiboda steadily transitioning into a comprehensive healthcare solutions provider.

6. Lingxi Cloud Completes Nearly RMB 100 Million in Series A Financing, Accelerating the Development of a Big Data and Large Model Platform for Brain-Computer Interfaces

Recently, Lingxi Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Lingxi Cloud"), a leading domestic brain-computer interface data platform and large-model enterprise, announced that it had completed nearly RMB 100 million in Series A financing in early 2026. The round was co-led by Sanbo Brain Hospital and the Bolian Brain Hospital Fund, which was jointly established by Sanbo Brain Hospital, Delian Capital, and the Shanghai Future Industry Fund. Follow-on investors included the Shanghai Future Industry Fund, Minjin Investment, Guo Hui (President of Shanghai Deji Hospital), Gongqingcheng Hongying, and the Xiong'an Angel Fund.

This financing round marks a significant milestone in the development of Lingxi Cloud, signaling strong recognition from both the capital markets and the industry of the company’s innovative capabilities in the fields of brain-computer interface (BCI) big data and large models. The funds raised will be primarily used to further strengthen the company’s leading position in clinical BCI big data and neurodynamic large models, as well as to advance clinical studies for the Class III medical device registration of its AI-based brain function assessment system for core indications such as depression and Alzheimer’s disease.